Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (453 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: paclitaxelchemotherapyconcurrentcanceradjuvant
  Phrases that lowered it: painhistory80allergic12
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 5.5% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 71.5% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: supportive care (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 6906 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Blinding: double (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy NCT01450163 · started 2011 · scored riskier than 28% of active trials completed
• Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain NCT03407430 · started 2016 · scored riskier than 93% of active trials terminated
• Efficacy and Safety of Pregabalin/Tramadol Combination Versus Pregabalin in Acute Pain of Neuropathic Origin NCT05324059 · started 2022 · scored riskier than 5% of active trials completed
• Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain NCT01701362 · started 2012 · scored riskier than 72% of active trials completed
• Effect of Pregabalin in Patients With Radiotherapy-related Neuropathic Pain NCT01869569 · started 2013 · scored riskier than 47% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.